Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 10/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 8/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.53 |
| ▸ | AKT2 | P31751 | 3/20 | 0.45 |
| ▸ | GSK3B | P49841 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.42 |
| ▸ | HTR3A | P46098 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4069007 | 0.98 | SLC6A4 (0.55) | SLC6A4SLC6A2SLC6A3AKT2GSK3B | |
| SCHEMBL12574569 | 0.86 | ADRB2 (0.48) | SLC6A4SLC6A2SLC6A3AKT2GSK3B | |
| SCHEMBL390679 | 0.86 | ADRB2 (0.48) | SLC6A4SLC6A2SLC6A3AKT2GSK3B | |
| SCHEMBL31091021 | 0.86 | ADRB2 (0.48) | SLC6A4SLC6A2SLC6A3AKT2GSK3B | |
| SCHEMBL2677241 | 0.86 | ADRB2 (0.48) | SLC6A4SLC6A2SLC6A3AKT2GSK3B | |
| Hydrochloric Acid SCHEMBL20474787 | 0.84 | ADRB2 (0.46) | SLC6A4SLC6A2SLC6A3AKT2GSK3B | |
| Hydrochloric Acid SCHEMBL20474788 | 0.84 | ADRB2 (0.46) | SLC6A4SLC6A2SLC6A3AKT2GSK3B | |
| SCHEMBL26921017 | 0.82 | SLC6A3 (0.49) | SLC6A4SLC6A2SLC6A3AKT2GSK3B | |
| SCHEMBL7456086 | 0.82 | OPRM1 (0.45) | SLC6A4SLC6A2SLC6A3AKT2GSK3B | |
| SCHEMBL3591892 | 0.81 | RPS6KB1 (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090253718-A1 | Pharmaceutical Compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2009-10-08 | — | — | US | disclosed |
| US-20090253718-A1 | Pharmaceutical Compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2009-10-08 | — | — | US | disclosed |
| US-20090253718-A1 | Pharmaceutical Compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2009-10-08 | — | — | US | disclosed |
| CN-101479263-A | Pharmaceutical compounds | ASTEX THERAPEUTICS LTD (GB) | 2009-07-08 | — | — | CN | disclosed |
| US-20090124610-A1 | PHARMACEUTICAL COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-05-14 | — | — | US | disclosed |
| US-20090124610-A1 | PHARMACEUTICAL COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-05-14 | — | — | US | disclosed |
| US-20090099213-A1 | Ortho-Condensed Pyridine and Pyrimidine Derivatives (e.g., Purines) as Protein Kinases Inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2009-04-16 | — | — | US | disclosed |
| US-20090099213-A1 | Ortho-Condensed Pyridine and Pyrimidine Derivatives (e.g., Purines) as Protein Kinases Inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2009-04-16 | — | — | US | disclosed |
| US-20090099213-A1 | Ortho-Condensed Pyridine and Pyrimidine Derivatives (e.g., Purines) as Protein Kinases Inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2009-04-16 | — | — | US | disclosed |
| EP-2016077-A2 | PHARMACEUTICAL COMPOUNDS | Astex Therapeutics Limited (GB) | 2009-01-21 | — | — | EP | disclosed |
| WO-2007125315-A2 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007125315-A2 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2007-11-08 | — | — | WO | disclosed |
| WO-2007125320-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2007-11-08 | — | — | WO | disclosed |
| EP-1812003-A1 | ORTHO- CONDENSED PYRIDINE AND PYRIMIDINE DERIVATIVES (E. G. PURINES) AS PROTEIN KINASES INHIBITORS | Astex Therapeutics Limited (GB) | 2007-08-01 | — | — | EP | disclosed |
| WO-2006046023-A1 | ORTHO- CONDENSED PYRIDINE AND PYRIMIDINE DERIVATIVES (E. G. PURINES) AS PROTEIN KINASES INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2006-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253718-A1 | Pharmaceutical Compounds | GRK3, CNKSR1, CSNK1G3 | SLC6A4 2464/4885SLC6A2 2275/4885SLC6A3 1631/4885 |
| US-20090124610-A1 | PHARMACEUTICAL COMPOUNDS | GRK3, GRK4, CDK1 | SLC6A4 1353/4885SLC6A2 927/4885SLC6A3 1314/4885 |
| US-20090099213-A1 | Ortho-Condensed Pyridine and Pyrimidine Derivatives (e.g., Purines) as Protein Kinases Inhibitors | OXSR1, CDK1, CDK3 | SLC6A4 3766/4885SLC6A2 3185/4885SLC6A3 2353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.